Zinc Finger Protein ZC3H13: Potential Drug Target Or Biomarker

Target Name: ZC3H13

NCBI ID: G23091

ZC3H13

Zinc Finger Protein ZC3H13: Potential Drug Target Or Biomarker

Zinc finger proteins (ZFPs) are a family of non-coding RNAs that play a crucial role in gene regulation and have been implicated in a wide range of cellular processes. ZC3H13, also known as zinc finger CCCH-type containing 13, is a ZFP that has been identified as a potential drug target or biomarker.

The zinc finger gene family is characterized by a conserved core structure that includes a nucleotide-binding oligomerization domain (NBO), a zinc finger domain, and a C-terminal hypervariable region (HVR). ZFPs are classified into different types based on the presence or absence of certain gene products, such as ZF1, ZF2, ZF3, and ZF4. ZC3H13 is a ZFH type, which means that it contains a zinc finger domain and a C-terminal hypervariable region.

ZC3H13 has been shown to play a role in a wide range of cellular processes, including cell growth, differentiation, and metabolism. For example, ZC3H13 has been shown to be involved in cell cycle progression, where it is thought to regulate the G1/S transition. Additionally, ZC3H13 has been shown to be involved in cell survival and has been implicated in the development of cancer.

As a potential drug target, ZC3H13 has been the focus of research into new treatments for various diseases, including cancer. Studies have shown that inhibiting ZC3H13 can be an effective way to treat cancer cells, especially in cases where the disease is caused by Activated T-cells (ATCs). This is because ZC3H13 is a key regulator of the T-cell receptor (TCR), which is responsible for cell survival and proliferation.

In addition to its potential as a drug target, ZC3H13 has also been identified as a potential biomarker for cancer. This is because its expression is often affected by the development of cancer, and therefore its levels can be used as a indicator of disease. Studies have shown that ZC3H13 expression is often elevated in cancer cells, and that inhibiting its expression can be an effective way to reduce cancer cell proliferation.

Overall, ZC3H13 is a ZFP that has been shown to play a crucial role in a wide range of cellular processes. Its potential as a drug target or biomarker makes it an attractive target for further research into the mechanisms of cancer development and treatment. As research continues to advance, it is likely that new insights into the biology of ZC3H13 will emerge, and its potential as a drug or biomarker will be further confirmed.

Protein Name: Zinc Finger CCCH-type Containing 13

Functions: Associated component of the WMM complex, a complex that mediates N6-methyladenosine (m6A) methylation of RNAs, a modification that plays a role in the efficiency of mRNA splicing and RNA processing (PubMed:29507755). Acts as a key regulator of m6A methylation by promoting m6A methylation of mRNAs at the 3'-UTR (By similarity). Controls embryonic stem cells (ESCs) pluripotency via its role in m6A methylation (By similarity). In the WMM complex, anchors component of the MACOM subcomplex in the nucleus (By similarity). Also required for bridging WTAP to the RNA-binding component RBM15 (RBM15 or RBM15B) (By similarity)

The "ZC3H13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZC3H13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets